×

Pfizer CEO: Ibrance drug well received by physicians

Monday, 1 Jun 2015 | 11:16 AM ET

Pfizer CEO Ian Read, discusses the PALOMA-3 trial for its oncology treatment Ibrance to treat breast cancer, drug pricing and competition in the pharmaceutical industry.